Related Experiment Video

Updated: Feb 21, 2026

Brain Ventricular Microinjections of Lipopolysaccharide into Larval Zebrafish to Assess Neuroinflammation and Neurotoxicity
07:31

Brain Ventricular Microinjections of Lipopolysaccharide into Larval Zebrafish to Assess Neuroinflammation and Neurotoxicity

Published on: August 23, 2022

3.9K

Protosappanin A exerts anti-neuroinflammatory effect by inhibiting JAK2-STAT3 pathway in lipopolysaccharide-induced

Li-Chao Wang1, Li-Xi Liao2, Ming-Bo Zhao2

  • 1State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.

Chinese Journal of Natural Medicines
|October 10, 2017
PubMed

Insights

Protosappanin A (PTA) reduces neuroinflammation by inhibiting key inflammatory markers and suppressing the JAK2/STAT3 pathway in microglia. This suggests PTA

Area of Science:

  • Neuroscience
  • Pharmacology
  • Immunology

Background:

  • Microglial activation drives neuroinflammation in diseases like Alzheimer's and Parkinson's.
  • Anti-neuroinflammatory agents offer potential therapeutic benefits.
  • Protosappanin A (PTA) is a bioactive compound from Caesalpinia sappan L.

Purpose of the Study:

  • To investigate the anti-neuroinflammatory effects of PTA on lipopolysaccharide (LPS)-stimulated BV2 microglia.
  • To explore the underlying molecular mechanisms of PTA's action.

Main Methods:

  • BV2 cells were stimulated with LPS to induce a neuroinflammatory response.
  • The effects of PTA on cytokine production (TNF-α, IL-1β, IL-6, MCP-1) were measured.
  • The JAK2/STAT3 signaling pathway activation (phosphorylation and nuclear translocation) was assessed.

Main Results:

  • PTA significantly inhibited TNF-α and IL-1β production in LPS-activated BV2 cells.
  • PTA dose-dependently reduced mRNA expression of IL-6, IL-1β, and MCP-1.
  • PTA suppressed the JAK2/STAT3 pathway by inhibiting JAK2 and STAT3 phosphorylation and STAT3 nuclear translocation.

Conclusions:

  • PTA exhibits significant anti-neuroinflammatory properties in microglia.
  • PTA acts, in part, by modulating the JAK2/STAT3 signaling pathway.
  • PTA represents a potential therapeutic agent for neuroinflammatory disorders.
Keywords:
BV2 microgliaJAK2-STAT3LipopolysaccharideNeuroinflammationProtosappanin A

More Related Videos

Magnetic Isolation of Microglial Cells from Neonate Mouse for Primary Cell Cultures07:23

Magnetic Isolation of Microglial Cells from Neonate Mouse for Primary Cell Cultures

Published on: July 25, 2022

3.7K
Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates09:12

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates

Published on: January 30, 2014

16.8K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.3K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K